DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020707/S-006 **SUPPLEMENT APPROVAL**

sanofi-aventis U.S. LLC
Attention: Debra Kolb
Specialist, US RAMP
55 Corporate Drive, Mail Stop 55A-430A
Bridgewater, NJ 08807-0912

Dear Ms. Kolb:

Please refer to your supplemental new drug application dated and received July 1, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Skelid® (tiludronate disodium) tablets.

We acknowledge receipt of your submissions dated December 9 and 22, 2009.

This supplemental new drug application provides for class labeling changes to the CONTRAINDICATIONS and WARNINGS Sections of the Package Insert. These labeling changes:

1. Contraindicate the use of Skelid® in patients who are unable to stand or sit upright for at least 30 minutes.
2. Provide in the WARNINGS Section (a) additional information regarding upper gastrointestinal adverse events associated with the use of oral bisphosphonates and (b) guidance to physicians regarding the use of Skelid® in patients with symptoms or signs of an upper gastrointestinal disorder.

Other changes in the Package Insert include addition of statements in the Information for Patients subsection of the PRECAUTIONS Section and the DOSAGE and ADMINISTRATION Section that patients should not lie down for at least 30 minutes after taking this medication.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## CONTENT OF LABELING

Please resubmit the enclosed content of labeling in structured product labeling (SPL) format as soon as possible, but no later than 14 days from the date of this letter. For administrative purposes, please designate this submission, "**SPL for approved NDA 020707/S-006**."

## PROMOTIONAL MATERIALS

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the following address or by facsimile at 301-847-8444:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

In addition, as required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

## LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
5600 Fishers Lane, Room 12B05
Rockville, MD 20857

## REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Karl Stiller, Regulatory Project Manager, at (301) 796-1993.

Sincerely,

*{See appended electronic signature page}*

Scott Monroe, M.D.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure
Content of Labeling

| Application Type/Number | Submission Type/Number | Submitter Name | Product Name |
|---|---|---|---|
| NDA-20707 | SUPPL-6 | SANOFI AVENTIS US LLC | SKELID (TILUDRONATE DISODIUM) ORAL TABS |

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

/s/

SCOTT E MONROE
03/19/2010